There are currently 2006 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
NCT04998396
Recruiting
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Gender:
ALL
Ages:
30 months and below
Trial Updated:
10/21/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Canavan Disease
Register for Updates
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT01042379
Recruiting
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Register for Updates
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT03681561
Recruiting
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Hodgkin Lymphoma
Register for Updates
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351
Recruiting
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828
Recruiting
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer sur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Advocate Illinois Masonic Medical Center, Chicago, Illinois
Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Register for Updates
Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT
NCT01356290
Recruiting
Patients with relapsed medulloblastoma, ependymoma and ATRT have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities. Antiangiogenetic therapy has emerged as new treatment option in solid malignancies. The frequent, metronomic schedule targets both proliferating tumor cells and endothelial cells, and minimizes toxicity. In this study the investigators will evaluate the use of biweekly... Read More
Gender:
ALL
Ages:
19 years and below
Trial Updated:
10/17/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent
Register for Updates
MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms
NCT05285553
Recruiting
The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
10/17/2024
Locations: SoLo Eye Care & Eyewear Gallery, Chicago, Illinois +1 locations
Conditions: Myopia
Register for Updates
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
NCT05629494
Recruiting
Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-specific antigen (PSA) level is the primary reason for prostate biopsy in \> 90% of cases. However, at the PSA levels which trigger prostate biopsy, often no cancer is found in prostate biopsy specimens. PSA test can be elevated due to reasons other than cancer such as inflammation or natural variation i... Read More
Gender:
MALE
Ages:
Between 18 years and 80 years
Trial Updated:
10/17/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Prostate Cancer, Prostate Inflammation, PSA
Register for Updates
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
NCT06636682
Recruiting
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also learn about the safety of FK-PC101. The main questions it aims to answer are: Does FK-PC101 delay or prevent the return of prostate cancer following surgery? What medical problems do participants (subjects) have when taking FK-PC101? Researchers will compare FK-PC101 to current treatment practice to... Read More
Gender:
MALE
Ages:
All
Trial Updated:
10/17/2024
Locations: University of Chicago Medicine, High-Risk and Advanced Prostate Cancer Clinic, Chicago, Illinois
Conditions: Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
Register for Updates
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
NCT04475926
Recruiting
This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), Limb-girdle muscular dystrophy type 2C (LGMD2C/R5), or Limb-girdle muscular dystrophy type 2A (LGMD2A/R1). These enrolled participants will be followed to evaluate mobility and pulmonary function for up to 5 years after enrollment for participants with LGMD2C/R5, LGMD2D/R3, and LGMD2E/R4 with a Nort... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
10/16/2024
Locations: Anne & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Limb-girdle Muscular Dystrophy
Register for Updates
Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT05315700
Recruiting
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Solid Tumors
Register for Updates
The PREDICTOR Study: Assessing Diagnostic Predictors of Airway Collapse in Patients With Obstructive Sleep Apnea
NCT05428839
Recruiting
This study is an exploratory, multicenter study of up to 300 subjects diagnosed with obstructive sleep apnea who are being evaluated for airway surgery. Subjects will undergo standard evaluation for airway surgery as part of standard of care. In addition to the standard airway assessment, a simple, non-invasive measurement of the width of the inside of each subjects mouth will be performed. This measurement takes 2-3 minutes to perform.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Sleep Apnea, Obstructive
Register for Updates